AHK-Cu is a synthetic copper(II) coordination complex of the tripeptide alanyl-histidyl-lysine (Ala-His-Lys). It is the position-1 analogue of the far better-known GHK-Cu, differing only in that alanine replaces glycine at the N-terminus. GHK occurs naturally in human plasma, saliva and urine and is a recognized collagen fragment; AHK is not a documented endogenous human peptide but a designed structural variant. It is a genuine three-residue peptide supplied as a metal complex, so its chemistry is dominated by copper coordination.
A single study underpins almost everything written about this compound
The primary record consists of one paper: Pyo and colleagues at Seoul National University, Archives of Pharmacal Research (2007). Using human hair follicles in ex vivo organ culture and cultured human dermal papilla cells, they reported that AHK-Cu at picomolar to nanomolar concentrations stimulated follicle elongation and dermal papilla cell proliferation, with an increased Bcl-2/Bax ratio and reduced cleaved caspase-3 and PARP. The authors noted that the reduction in apoptotic cells measured by flow cytometry was not statistically significant, and framed their conclusion as a proposal rather than a demonstration. A 2026 review of short peptides for hair loss in Biomedicines classifies the evidence status as experimental only, identifying no human clinical trials.
A recurring accuracy problem deserves direct attention. Descriptions of AHK-Cu commonly assert that it raises VEGF, stimulates dermal fibroblast proliferation and suppresses TGF-beta1. Those statements trace to the opening background sentence of the 2007 abstract, which characterizes copper tripeptides as a class — a literature built overwhelmingly on GHK-Cu — and were not experimental findings about AHK-Cu in that paper or elsewhere.
Categorization is a second issue. AHK-Cu is routinely grouped as a skin compound, yet the only published experimental work concerns hair follicles and dermal papilla cells. No study has examined it in wound healing, collagen synthesis, photoaging or dermal remodeling models; the skin association rests on structural similarity to GHK-Cu rather than on direct evidence. Even the coordination geometry usually quoted is read across from GHK-Cu, as no structural study of AHK-Cu itself has been published.
What is missing from the record is as informative as what is present. There are no pharmacokinetic data of any kind — no half-life, bioavailability, ADME characterization or measurement of skin penetration — no animal efficacy studies, no toxicology package and no registered clinical trials. AHK-Cu remains a preclinical research compound with one supporting paper, and it is not approved for human use in any jurisdiction.